Cetuximab
1
Reactions 1509, p13 - 12 Jul 2014 S Cetuximab Acneiform rash: case report A patient [age and sex not stated] developed acneiform rash while receiving cetuximab. The patient, who had locally advanced non-small cell lung cancer, received cetuximab once weekly for 6 weeks [dose and route not stated], with cisplatin and radiotherapy. The patient developed grade 2 or 3 acneiform rash [grade not clearly stated; duration of treatment to reaction onset not stated]. Cetuximab was discontinued, and the patient received treatment on demand. Author comment: "One patient discontinued treatment because of skin toxicity." Van Den Heuvel M. Prophylactic oral minocycline and topical pimecrolimus on demand for cetuximab induced acne-like rash in patients with NSCLC stage 3. Supportive Care in Cancer 19 (Suppl.): S110 abstr. 96, No. 2, Jun 2011. Available from: URL: http://doi.org/10.1007/s00520-011-1184-y - Netherlands Antilles 803105625 1 Reactions 12 Jul 2014 No. 1509 0114-9954/14/1509-0001/$14.95 Adis © 2014 Springer International Publishing AG. All rights reserved
Transcript of Cetuximab
Reactions 1509, p13 - 12 Jul 2014
SCetuximab
Acneiform rash: case reportA patient [age and sex not stated] developed acneiform rash
while receiving cetuximab. The patient, who had locallyadvanced non-small cell lung cancer, received cetuximab onceweekly for 6 weeks [dose and route not stated], with cisplatinand radiotherapy. The patient developed grade 2 or 3acneiform rash [grade not clearly stated; duration of treatmentto reaction onset not stated]. Cetuximab was discontinued,and the patient received treatment on demand.
Author comment: "One patient discontinued treatmentbecause of skin toxicity."Van Den Heuvel M. Prophylactic oral minocycline and topical pimecrolimus ondemand for cetuximab induced acne-like rash in patients with NSCLC stage 3.Supportive Care in Cancer 19 (Suppl.): S110 abstr. 96, No. 2, Jun 2011. Availablefrom: URL: http://doi.org/10.1007/s00520-011-1184-y - NetherlandsAntilles 803105625
1
Reactions 12 Jul 2014 No. 15090114-9954/14/1509-0001/$14.95 Adis © 2014 Springer International Publishing AG. All rights reserved
